tirzepatide naion Semaglutide or and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes In this case series study,

The papers authors are an international team of obesity experts led by the co-chairs of the EASO Obesity Management Working Group, who are Dr Andreea Ciudin, Vall d'Hebron University Hospital, Autonomous University Barcelona, Barcelona, Spain

Considering the significant negative impact of PAD in diabetic patients, international clinical guidelines have recommended using glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT-2 inhibitors) in individuals with type 2 diabetes and PAD to reduce the risk of major adverse cardiovascular events

Common Questions About GLP-1 Treatments Are GLP-1 Treatments Safe

560Ministry of Statistics & Programme Implementation, Government of India (2014) Available online at: (Accessed October 19, 2024)

J Cell Signal 1(4):160168